BMRN
HEALTHCAREBiomarin Pharmaceutical Inc
$54.60+1.36 (+2.55%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BMRN Today?
No stock-specific AI insight has been generated for BMRN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$50.76$66.28
$54.60
Fundamentals
Market Cap$10.6B
P/E Ratio39.3
EPS$1.39
Dividend Yield—
Dividend / Share—
ROE0.0%
Profit Margin0.1%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding193.3M
BMRN News
21 articles- Is BioMarin Pharmaceutical Inc. (BMRN) One of the Top Cheap Stocks to Buy With the Biggest Upside Potential?Yahoo Finance·May 7, 2026
- Is BioMarin Pharmaceutical (BMRN) Pricing Reflect Its Rare Disease Growth And Voxzogo ProspectsYahoo Finance·May 6, 2026
- BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedYahoo Finance·May 5, 2026
- BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush SaysYahoo Finance·May 5, 2026
- BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley SaysYahoo Finance·May 5, 2026
- BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 4, 2026
- BioMarin Pharmaceutical Q1 Earnings Call HighlightsMarketbeat·May 4, 2026
- BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag EstimatesYahoo Finance·May 4, 2026
- BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue EstimatesYahoo Finance·May 4, 2026
- BioMarin Reports First Quarter 2026 Financial and Operating ResultsYahoo Finance·May 4, 2026
- BioMarin (BMRN) Q4 2025 Earnings TranscriptMotley Fool·May 4, 2026
- BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To ExpectYahoo Finance·May 4, 2026
- BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual MeetingYahoo Finance·May 2, 2026
- BioMarin acquires Amicus Therapeutics for $4.8bnPharmaceutical-technology·Apr 28, 2026
- Snap upgraded, Pinterest downgrade: Wall Street's top analyst callsYahoo Finance·Apr 27, 2026
- BioMarin Completes Acquisition of Amicus TherapeuticsYahoo Finance·Apr 27, 2026
- BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ETYahoo Finance·Apr 27, 2026
- CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)The Motley Fool·Apr 25, 2026
- BioMarin Announces Board Leadership TransitionYahoo Finance·Apr 21, 2026
- Is BioMarin Pharmaceutical (BMRN) Now Attractive After Prolonged Share Price Weakness?Yahoo Finance·Apr 12, 2026
All 21 articles loaded
Price Data
Open$53.91
Previous Close$53.24
Day High$54.29
Day Low$53.56
52 Week High$66.28
52 Week Low$50.76
52-Week Range
$50.76$66.28
$54.60
Fundamentals
Market Cap$10.6B
P/E Ratio39.3
EPS$1.39
Dividend Yield—
Dividend / Share—
ROE0.0%
Profit Margin0.1%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding193.3M
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—